In vivo treatment of melanoma (B16F10) with a homeopathic agent and with a cytokine (IFN-α)

Oncology Research

Volumn 16, Issue 5, 2006, Pages 211-216

  Pascual Carpe, Fernando ^a   Vicente Ortega, Vicente ^a,b   Campos Aranda, Matilde ^a   Yañez Gascón, Josefa ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b Campus de Espinardo   (Spain)

Author keywords

B16F10 melanoma; C57BL 6J; IFN ; Lymphomyosot; Treatment

Indexed keywords

ALPHA INTERFERON; HOMEOPATHIC AGENT; LYMPHOMYOSOT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; IN VIVO STUDY; MALE; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VOLUME;

EID: 33846808981     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783981099     Document Type: Article

References (20)

1. Mohr, P.; Weishentahl, M.; Hauschild, A. Adjuvant therapy in melanoma. Onkologie 26:227-233; 2003.
2. Blank, V.; Roguin, L. Interferon alpha: A protein for therapeutic use. (El interferón alfa: una proteína de uso terapéutico). Ciencia Hoy 12:1-4; 2003.
3. Schraub, S. Unproven methods in cancer: A worldwide problem. Support Cancer Care 8:10-15; 2000.
4. Richardson, M. A.; Straus, S. E. Complementary and alternative medicine: Opportunities and challenges for cancer management and research. Semin. Oncol. 6:531-545; 2002.
5. Marks, R. Epidemiology of melanoma. Clin. Exp. Dermatol. 25:459-463; 2000.
6. Hansson, J. Systemic therapy of malignant melanoma. Med. Oncol. 14(2):73-81; 1997.
7. Lee, M. L.; Tomsu, K.; Von Eschen, K. B. Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. Melanoma Res. 10(1):81-92; 2000.
8. Masback, A.; Olsson, H.; Westerdahl, J.; et al. Prognostic factors in invasive cutaneous malignant melanoma: A population-based study and review. Melanoma Res. 11(5):435-445; 2001.
9. Monfort, H. A new homeopathic approach to neoplastic diseases: From cell destruction to carcinogen-induced apoptosis. Br. Homeopath. J. 89(2):78-83; 2000.
10. Pathak, S.; Multani, A. S.; Banerji, P.; Banerji, P. Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer. Int. J. Oncol. 23(4):975-982; 2003.
11. Sabel, M. S.; Sondak, V. K. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 8:451-458; 2003.
12. Eggermont, A. M.; Kleeberg, U. R.; Ruiter, D. J.; Suciu, S. The European Organization for Research and Treatment of Cancer Melanoma Group Trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b. Alexandria, VA: American Society of Clinical Oncology; 2001:88-93.
13. Frank, S. J.; Meyers, M. Interferon as adjuvant therapy for high risk melanoma. Melanoma Lett. 13:1-4; 1995.
14. Prell, R. A.; Li, B.; Lin, J. M.; et al. Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res. 65(6):2449-2456; 2005.
15. Schmolz, M.; Metelmann, H. The immunopharmacological effect of Lymphomyosot components. (Efecto inmunofarmacológico de componentes de Lymphomyosot). Med. Biol. 16(2):46-52; 2003.
16. Ricken, K. H. Lymphomyosot: The link between the mesenchyme and the lymphatic system. (Eslabón entre el mesénquima y el sistema linfático). Med. Biol. No. 2; 1993.
17. Russell-Jones, R. Interferon-alpha therapy for melanoma. Clin. Exp. Dermatol. 25(1):1-6; 2000.
18. Hancock, B. W.; Harris, S.; Wheatley, K.; Gore, M. Adjuvant interferon-alpha in malignant melanoma: Current status. Cancer Treat. Rev. 26(2):81-89; 2000.
19. Krepler, C.; Certa, U.; Wacheck, V.; et al. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J. Invest. Dermatol. 123(4):664-669; 2004.
20. Badgwell, B.; Lesinski, G. B.; Magro, C.; et al. The antitumoral effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J. Surg. Res. 116(1):129-136; 2004.